Survival Gains, Savings With Next-Generation Sequencing in N

The modeling study shows "clinically meaningful" gains in survival and lower costs with NGS over single-gene testing in metastatic nonsquamous NSCLC.

Related Keywords

New York , United States , Ohio , Fred Hirsch , Nathan Pennell , Cleveland Clinic Lung Cancer Program , Drug Administration , Tisch Cancer Institute At Mount Sinai , National Comprehensive Cancer Network , Thoracic Oncology , Tisch Cancer Institute , Mount Sinai , New York City , Medscape Medical , Lung Cancer , Ung Carcinoma , Ancer Lung , Dna Sequencing , Genomics , Genomic Medicine , Edicine Genomic , Biologic Therapy , Targeted Therapy , Small Cell Lung Cancer , Cancer , Alignant Neoplasia , Arcinoma , Lung , Oncogene , Genetic Testing , Anaplastic Lymphoma Kinase Alk , Lk Tyrosine Kinase Receptor , D246 Cluster Of Differentiation 246 , Biomarker , Iological Marker , Kbraf , Clinical Guidelines , Guidelines ,